Logo image
Advances in inclusion body myositis: genetics, pathogenesis and clinical aspects
Journal article   Peer reviewed

Advances in inclusion body myositis: genetics, pathogenesis and clinical aspects

M. Needham and F.L. Mastaglia
Expert Opinion on Orphan Drugs, Vol.5(5), pp.431-443
04/2017
url
Link to Published Version *Subscription may be requiredView

Abstract

Introduction: Inclusion body myositis is the most common acquired muscle disease affecting older adults. It has an insidious onset with a very specific pattern of muscle involvement, but the aetiopathogenesis is still unknown. Pathologically the combination of inflammatory changes, degenerative changes as well as mitochondrial and nuclear changes are seen, and probably all contribute to the loss of muscle, however the primary abnormality remains a mystery. Treatment is currently supportive, but clinical trials are ongoing and are directed at new targets. Areas covered: Clinical profile, genetic susceptibility, pathogenesis and treatment Expert opinion: Understanding the aetiopathogeneis is vital to identify future treatment targets. In addition, understanding the natural history and the roles of biomarkers including the anti-CN1a antibody is vital for designing future clinical trials in IBM, to be properly designed and of sufficient duration to detect clinically significant changes.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics
1 Clinical & Life Sciences
1.106 Rheumatology
1.106.1684 Dermatomyositis
Web Of Science research areas
Pharmacology & Pharmacy
ESI research areas
Pharmacology & Toxicology
Logo image